ondasdechoque.org
PT-BR

Post-stroke spasticity and motor function · Follow-up analysis · 2025

Does a double dose of shockwave change calf muscles more after a stroke?

This analysis compared a double dose of focused shockwave (two calf muscles) with the standard dose (one calf muscle) after a stroke. Over 24 weeks, ultrasound showed similar muscle fibre length and angle in both groups. One ultrasound measure of muscle stiffness changed differently between them.

adults with ankle stiffness after a stroke
39
sessions over 2 weeks
4
weeks of follow-up
24

Good to know: A closer look at ultrasound results from an earlier trial of 39 people; both groups had shockwave and usual rehab.

Yang SM, Lin HH, Chen YH, et al. Journal of Neuroengineering and Rehabilitation, 2025 · Read the paper ↗

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

The treatment

Double dose

Focused, twice a week for 2 weeks

Focused wavesMeet at a focal zone below the skin
Sessions
4, two a week
Pulses
4,000 per session · 2,000 each to the two main calf muscles, aimed with ultrasound
Strength
0.10–0.134mJ/mm² · 4 per second
Numbing
None
Device
Not named in the paper
Everyone also got
Usual rehabilitation

Standard dose

Focused, twice a week for 2 weeks

Focused wavesMeet at a focal zone below the skin
Sessions
4, two a week
Pulses
2,000 per session · all to the main calf muscle, aimed with ultrasound
Strength
0.10–0.134mJ/mm² · 4 per second
Numbing
None
Device
Not named in the paper
Everyone also got
Usual rehabilitation

Compared with: A standard dose of the same treatment: half the pulses, to the main calf muscle only

Settings are what each study used, not a prescription.

Who took part

39 adults with stiff ankle muscles after a stroke on one side of the body (19 double dose, 20 standard dose).

Double dose19 people
Standard dose20 people

Side effects

Side effects were not reported in this analysis. Paracetamol was allowed after treatment.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

Adults after unilateral stroke with ankle plantar-flexor spasticity above MAS grade 1. Baseline table lists n=19 double-dose and n=20 control; follow-up denominators varied with about 15% attrition at weeks 12 and 24.

Double-dose focused ESWT19enrolled

Baseline table lists n=19; source says roughly 15% loss at weeks 12 and 24 and available-case analysis, so later outcome denominators vary and are not reconstructed.

Control-dose focused ESWT20enrolled

Baseline table lists n=20; source says roughly 15% loss at weeks 12 and 24 and available-case analysis, so later outcome denominators vary and are not reconstructed.

Ultrasound strain elastography1 reported outcome
01
Baseline through week 24 after treatment

Strain elastography

Ultrasound strain elastography Source-reported elastography measure; unit not stated in table

REPORTED COMPARISON TESTp = 0.008

Change over time differed between dose groups

GEE group × time interaction

The group-by-time interaction was statistically significant. The accessible table does not provide a between-group effect estimate or confidence interval, so magnitude and clinical importance remain unquantified.

Analysis details and source

Main effects: group p=.222; time p=.209. Avoid interpreting the interaction as proof that double dose is better without the trajectory estimates.

Ultrasonographic muscle measure10 reported outcomes
02
Baseline

Pennation angle

Ultrasonographic muscle measure degrees

Pennation angle · Baseline · means
GroupnBaselineFollow-up
Double-dose focused ESWT19—15.58 (SD 4.78)
Control-dose focused ESWT20—16.91 (SD 4.15)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.458; control 0.861

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.

03
Week 1 after treatment

Pennation angle

Ultrasonographic muscle measure degrees

Pennation angle · Week 1 after treatment · means
GroupnBaselineFollow-up
Double-dose focused ESWT19—16.13 (SD 3.81)
Control-dose focused ESWT20—15.87 (SD 2.88)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.458; control 0.861

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.

04
Week 4 after treatment

Pennation angle

Ultrasonographic muscle measure degrees

Pennation angle · Week 4 after treatment · means
GroupnBaselineFollow-up
Double-dose focused ESWT19—16.12 (SD 3.83)
Control-dose focused ESWT20—16.59 (SD 2.6)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.458; control 0.861

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.

05
Week 12 after treatment

Pennation angle

Ultrasonographic muscle measure degrees

Pennation angle · Week 12 after treatment · means
GroupnBaselineFollow-up
Double-dose focused ESWT——16.46 (SD 4.31)
Control-dose focused ESWT——15.91 (SD 3.43)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.458; control 0.861

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time. Table 2 prints no per-visit n: the authors report about 15% loss to follow-up in each group at weeks 12 and 24 and used available-case analysis without imputation, so fewer than the 19 and 20 participants contributed to these means. The exact numbers are not reported, so n is left blank.

06
Week 24 after treatment

Pennation angle

Ultrasonographic muscle measure degrees

Pennation angle · Week 24 after treatment · means
GroupnBaselineFollow-up
Double-dose focused ESWT——15.02 (SD 3.89)
Control-dose focused ESWT——16.99 (SD 1.95)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.458; control 0.861

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time. Table 2 prints no per-visit n: the authors report about 15% loss to follow-up in each group at weeks 12 and 24 and used available-case analysis without imputation, so fewer than the 19 and 20 participants contributed to these means. The exact numbers are not reported, so n is left blank. Source contradiction: the Results text says the double-dose mean PA "increased slightly from 15.58 degrees (SD = 4.78) at baseline to 15.02 degrees (SD = 3.89) at week 24"; the printed means show a slight decrease. The Table 2 values are kept as printed.

07
Baseline

Muscle fascicle length

Ultrasonographic muscle measure cm

Muscle fascicle length · Baseline · means
GroupnBaselineFollow-up
Double-dose focused ESWT19—4.56 (SD 0.53)
Control-dose focused ESWT20—4.3 (SD 0.45)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.938; control 0.177

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.

08
Week 1 after treatment

Muscle fascicle length

Ultrasonographic muscle measure cm

Muscle fascicle length · Week 1 after treatment · means
GroupnBaselineFollow-up
Double-dose focused ESWT19—4.83 (SD 0.69)
Control-dose focused ESWT20—4.57 (SD 0.59)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.938; control 0.177

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.

09
Week 4 after treatment

Muscle fascicle length

Ultrasonographic muscle measure cm

Muscle fascicle length · Week 4 after treatment · means
GroupnBaselineFollow-up
Double-dose focused ESWT19—4.32 (SD 0.81)
Control-dose focused ESWT20—4.5 (SD 0.76)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.938; control 0.177

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.

10
Week 12 after treatment

Muscle fascicle length

Ultrasonographic muscle measure cm

Muscle fascicle length · Week 12 after treatment · means
GroupnBaselineFollow-up
Double-dose focused ESWT——4.68 (SD 0.62)
Control-dose focused ESWT——4.56 (SD 0.77)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.938; control 0.177

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time. Table 2 prints no per-visit n: the authors report about 15% loss to follow-up in each group at weeks 12 and 24 and used available-case analysis without imputation, so fewer than the 19 and 20 participants contributed to these means. The exact numbers are not reported, so n is left blank.

11
Week 24 after treatment

Muscle fascicle length

Ultrasonographic muscle measure cm

Muscle fascicle length · Week 24 after treatment · means
GroupnBaselineFollow-up
Double-dose focused ESWT——4.27 (SD 0.36)
Control-dose focused ESWT——4.23 (SD 0.54)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

REPORTED COMPARISON TESTp double-dose 0.938; control 0.177

One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison

Within-group Friedman tests; GEE group/time analysis reported separately

Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.

Analysis details and source

Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time. Table 2 prints no per-visit n: the authors report about 15% loss to follow-up in each group at weeks 12 and 24 and used available-case analysis without imputation, so fewer than the 19 and 20 participants contributed to these means. The exact numbers are not reported, so n is left blank.

Exploratory post hoc association30 reported outcomes
12
Across reported assessment data

Elastography and MAS correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.017Uncertainty interval unavailablep = 0.870

Elastography vs MAS; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=-0.017, p=0.870. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

13
Across reported assessment data

Pennation angle and MAS correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.232Uncertainty interval unavailablep = 0.032

Pennation angle vs MAS; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=0.232, p=0.032. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

14
Across reported assessment data

Muscle fascicle length and MAS correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.21Uncertainty interval unavailablep = 0.156

Muscle fascicle length vs MAS; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=-0.21, p=0.156. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

15
Across reported assessment data

Elastography and MAS correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.073Uncertainty interval unavailablep = 0.488

Elastography vs MAS; control ESWT group

Exploratory post hoc correlation: Pearson r=-0.073, p=0.488. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

16
Across reported assessment data

Pennation angle and MAS correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.003Uncertainty interval unavailablep = 0.982

Pennation angle vs MAS; control ESWT group

Exploratory post hoc correlation: Pearson r=0.003, p=0.982. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

17
Across reported assessment data

Muscle fascicle length and MAS correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.207Uncertainty interval unavailablep = 0.145

Muscle fascicle length vs MAS; control ESWT group

Exploratory post hoc correlation: Pearson r=-0.207, p=0.145. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

18
Across reported assessment data

Elastography and MTS correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.185Uncertainty interval unavailablep = 0.072

Elastography vs MTS; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=0.185, p=0.072. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

19
Across reported assessment data

Pennation angle and MTS correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.08Uncertainty interval unavailablep = 0.469

Pennation angle vs MTS; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=-0.08, p=0.469. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

20
Across reported assessment data

Muscle fascicle length and MTS correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.3Uncertainty interval unavailablep = 0.040

Muscle fascicle length vs MTS; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=0.3, p=0.040. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

21
Across reported assessment data

Elastography and MTS correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.125Uncertainty interval unavailablep = 0.234

Elastography vs MTS; control ESWT group

Exploratory post hoc correlation: Pearson r=-0.125, p=0.234. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

22
Across reported assessment data

Pennation angle and MTS correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.01Uncertainty interval unavailablep = 0.931

Pennation angle vs MTS; control ESWT group

Exploratory post hoc correlation: Pearson r=-0.01, p=0.931. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

23
Across reported assessment data

Muscle fascicle length and MTS correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.123Uncertainty interval unavailablep = 0.392

Muscle fascicle length vs MTS; control ESWT group

Exploratory post hoc correlation: Pearson r=-0.123, p=0.392. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

24
Across reported assessment data

Elastography and PROM correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.164Uncertainty interval unavailablep = 0.111

Elastography vs PROM; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=0.164, p=0.111. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

25
Across reported assessment data

Pennation angle and PROM correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.129Uncertainty interval unavailablep = 0.240

Pennation angle vs PROM; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=-0.129, p=0.240. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

26
Across reported assessment data

Muscle fascicle length and PROM correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.423Uncertainty interval unavailablep = 0.003

Muscle fascicle length vs PROM; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=0.423, p=0.003. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

27
Across reported assessment data

Elastography and PROM correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.094Uncertainty interval unavailablep = 0.374

Elastography vs PROM; control ESWT group

Exploratory post hoc correlation: Pearson r=-0.094, p=0.374. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

28
Across reported assessment data

Pennation angle and PROM correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.045Uncertainty interval unavailablep = 0.704

Pennation angle vs PROM; control ESWT group

Exploratory post hoc correlation: Pearson r=0.045, p=0.704. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

29
Across reported assessment data

Muscle fascicle length and PROM correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.063Uncertainty interval unavailablep = 0.663

Muscle fascicle length vs PROM; control ESWT group

Exploratory post hoc correlation: Pearson r=0.063, p=0.663. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

30
Across reported assessment data

Elastography and Timed Up and Go test correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.149Uncertainty interval unavailablep = 0.148

Elastography vs Timed Up and Go test; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=-0.149, p=0.148. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

31
Across reported assessment data

Pennation angle and Timed Up and Go test correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.077Uncertainty interval unavailablep = 0.481

Pennation angle vs Timed Up and Go test; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=0.077, p=0.481. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

32
Across reported assessment data

Muscle fascicle length and Timed Up and Go test correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.644Uncertainty interval unavailablep <0.001

Muscle fascicle length vs Timed Up and Go test; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=-0.644, p=<0.001. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

33
Across reported assessment data

Elastography and Timed Up and Go test correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.004Uncertainty interval unavailablep = 0.056

Elastography vs Timed Up and Go test; control ESWT group

Exploratory post hoc correlation: Pearson r=-0.004, p=0.056. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source. Source contradiction: with 20 control participants assessed at up to five visits, a Pearson r of −0.004 corresponds to p of about 0.97–0.99, not the printed 0.056; one of the two printed values is probably a typo. Both are kept as printed.

34
Across reported assessment data

Pennation angle and Timed Up and Go test correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.105Uncertainty interval unavailablep = 0.374

Pennation angle vs Timed Up and Go test; control ESWT group

Exploratory post hoc correlation: Pearson r=-0.105, p=0.374. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

35
Across reported assessment data

Muscle fascicle length and Timed Up and Go test correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.245Uncertainty interval unavailablep = 0.084

Muscle fascicle length vs Timed Up and Go test; control ESWT group

Exploratory post hoc correlation: Pearson r=-0.245, p=0.084. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

36
Across reported assessment data

Elastography and Barthel index correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.017Uncertainty interval unavailablep = 0.870

Elastography vs Barthel index; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=0.017, p=0.870. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

37
Across reported assessment data

Pennation angle and Barthel index correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r-0.006Uncertainty interval unavailablep = 0.956

Pennation angle vs Barthel index; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=-0.006, p=0.956. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

38
Across reported assessment data

Muscle fascicle length and Barthel index correlation (double-dose)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.063Uncertainty interval unavailablep = 0.683

Muscle fascicle length vs Barthel index; double-dose ESWT group

Exploratory post hoc correlation: Pearson r=0.063, p=0.683. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

39
Across reported assessment data

Elastography and Barthel index correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.124Uncertainty interval unavailablep = 0.237

Elastography vs Barthel index; control ESWT group

Exploratory post hoc correlation: Pearson r=0.124, p=0.237. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

40
Across reported assessment data

Pennation angle and Barthel index correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.171Uncertainty interval unavailablep = 0.144

Pennation angle vs Barthel index; control ESWT group

Exploratory post hoc correlation: Pearson r=0.171, p=0.144. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

41
Across reported assessment data

Muscle fascicle length and Barthel index correlation (control)

Exploratory post hoc association Pearson correlation coefficient r

Pearson r0.296Uncertainty interval unavailablep = 0.053

Muscle fascicle length vs Barthel index; control ESWT group

Exploratory post hoc correlation: Pearson r=0.296, p=0.053. This is an association, not a causal or treatment effect.

Analysis details and source

Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.

How treatment was delivered
Focused ESWT settings

4 Hz; EFD 0.10–0.134 mJ/mm²; four sessions, twice weekly for two weeks; ultrasound-guided targeting; no local anesthetic.

Dose groups

Double-dose: 4,000 pulses/session (2,000 gastrocnemius, 2,000 soleus). Control: 2,000 pulses/session to gastrocnemius only. Both groups continued usual rehabilitation.

HARMS & TOLERABILITY

Adverse-event counts were not reported in the analyzed article. Paracetamol was permitted after treatment and NSAIDs discouraged.

LIMITS OF THE ANALYSIS

Secondary analysis of an existing trial; the analysis is exploratory for ultrasound architecture. Available-case analysis without imputation and approximately 15% attrition at later assessments may bias results.

Table 1 reports baseline n=19 and n=20, while some percentages imply different denominators. This internal denominator inconsistency and changing follow-up counts require caution; no missing denominators were reconstructed.

Ultrasound was assessed by one assessor; no healthy comparison group or neurophysiological assessment was included. Supplementary material was not available.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Secondary analysis of an existing trial; the analysis is exploratory for ultrasound architecture. Available-case analysis without imputation and approximately 15% attrition at later assessments may bias results.
  • Table 1 reports baseline n=19 and n=20, while some percentages imply different denominators. This internal denominator inconsistency and changing follow-up counts require caution; no missing denominators were reconstructed.
  • Ultrasound was assessed by one assessor; no healthy comparison group or neurophysiological assessment was included. Supplementary material was not available.
Research review

Source-linked critical reading

Post hoc analysis of a randomized trial

Reading depthMaterial consulted
Technical source record

Full-text XML and all four table-wraps (baseline characteristics, within-group measures, GEE tests and correlations) read directly; figure caption, discussion, limitations and end-matter read; supplements unavailable.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design

Secondary analysis of a previously published randomized dose-comparison trial. Ultrasound outcomes were assessed at baseline and 1, 4, 12 and 24 weeks after treatment; clinical associations were exploratory.

Participants

Adults with unilateral stroke and plantar-flexor spasticity above MAS grade 1. Baseline table lists 19 participants in the double-dose group and 20 in control; approximately 15% were lost at week 12 and week 24.

Protocol

Focused ESWT, 4 Hz, EFD 0.10–0.134 mJ/mm², four sessions over two weeks. Double-dose: 4,000 pulses/session, 2,000 each to gastrocnemius and soleus. Control: 2,000 pulses/session to gastrocnemius. Ultrasound guided targeting; no local anesthetic. Usual rehabilitation continued.

Comparator

The control was an active ESWT dose, not sham or no treatment. Both groups also continued usual rehabilitation and orthoses as applicable.

Outcomes

Primary analysis considered pennation angle (PA), muscle fascicle length (MFL) and strain elastography. No between-group time interaction was found for PA (p=.569) or MFL (p=.772); elastography had a group-by-time interaction (p=.008). MFL had a time effect (p=.007), without a group effect.

Between-group findings

The authors conclude there were no significant between-group differences in PA or MFL, while changes in stiffness measured by strain elastography differed between the groups over time. Exploratory correlations in the double-dose arm linked MFL with MTS (r=.300), PROM (r=.423) and TUG (r=−.644); these are associations, not treatment effects or causal mechanisms.

Harms

Adverse-event counts are not reported in the article results. Paracetamol was permitted after treatment; NSAIDs were discouraged.

Limitations

This is a secondary analysis of a small trial with available-case handling and about 15% loss at later follow-ups. No healthy control group was included; ultrasound was assessed by one assessor. The clinical correlation analyses were within-group and exploratory. Supplementary files were cited but not available in the retrieved XML.

Applicability

The findings concern ultrasound architecture in post-stroke ankle spasticity and compare two active doses. They do not establish dose superiority for patient-important function or generalize to other causes or stages of spasticity.

Research needs

Larger trials should prespecify ultrasound and patient-important outcomes, retain participants through long-term visits, report uncertainty and missing-data handling, and test dose differences in a design powered for interaction effects.

THE ORIGINAL SOURCE

Read the original article.

Dose-response effectiveness of focused shockwave therapy on ultrasonographic muscular properties in patients with stroke exhibiting ankle spasticity.

Yang SM, Lin HH, Chen YH, Lu YL, Wu CH, Chen WS, Lin MT. · Journal of neuroengineering and rehabilitation · 2025

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →